Premium
Prolonged infusion of arabinosyl cytosine in childhood leukemia
Author(s) -
Wang Jaw J.,
Selawry Oleg S.,
Vietti Teresa J.,
Bodey Gerald P.
Publication year - 1970
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197001)25:1<1::aid-cncr2820250102>3.0.co;2-n
Subject(s) - medicine , refractory (planetary science) , leukemia , acute lymphocytic leukemia , acute leukemia , myelocytic leukemia , toxicity , chemotherapy , complete remission , childhood leukemia , gastroenterology , surgery , anesthesia , lymphoblastic leukemia , physics , astrobiology
Arabinosyl cytosine (ara‐C) was administered by continuous intravenous infusion to children with acute leukemia refractory to conventional chemotherapy. The dosage was 150 mg to 200 mg/M 2 of body surface area per 24 hours for 5 days, repeated every 2 weeks. Forty‐six children were admitted to this study. Thirty‐four had acute lymphocytic leukemia, and 12 had acute myelocytic leukemia. Of the 34 children with acute lymphocytic leukemia, one achieved complete hematologic remission, 3 achieved good partial remission, 9 had inadequate trials of the agent, and 21 failed to show any response to this agent. Of the 12 children with acute myelocytic leukemia, 2 had complete remission, one achieved good partial remission, 5 had inadequate trials of the agent, and 4 failed to show any response. Myelosuppression was the limiting toxicity. Prolonged infusion of ara‐C probably offers no advantage over rapid intravenous injections for the induction of remissions in children with acute lymphocytic leukemia.